Previous 10 | Next 10 |
3 Tips for Mitigating Risk With Penny Stocks Penny stocks are a popular option for those looking to increase their investment portfolios and potentially create a return on their investments. While penny stocks can be a great way to get into trading, they also come with higher levels of ri...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com The trading week is almost done but we’ve still got the biggest pre-market stock movers to go over for Friday! Moving stocks this morning are clinical trials, public offerings, e...
Short Squeeze Penny Stocks to Watch Before Next Week There’s no shortage of volatility in the stock market today. Penny stocks are some of the assets that demonstrate this phenomenon. Today we’ll talk about a few more companies that have seen more significant bearish bets placed...
3 Factors to Consider When Buying Biotech Penny Stocks Penny stocks in the biotech sector can be a great way to make money in the stock market. While these stocks are often overlooked by major investors, they can offer huge returns if you know what to look for. Here are three reasons wh...
Palm Beach, FL – November 10, 2022 – FinancialNewsMedia.com News Commentary – The pancreatic cancer treatment market is fiercely competitive. To maintain the escalating market competition, the market participants are implementing methods including increased ...
NEUROBO ANNOUNCES CLOSING OF $32.3 MILLION UNDERWRITTEN PUBLIC OFFERING INCLUDING FULL EXERCISE OF OVERALLOTMENT OPTION AND CONCURRENT PRIVATE PLACEMENT PR Newswire CLOSES EXCLUSIVE LICENSE OF ASSETS FROM DONG-A BOSTON , Nov. 8, 2022 /PRNewswi...
NeuroBo Pharmaceuticals ( NASDAQ: NRBO ) stock fell ~43% on Friday after the company priced a public offering to raise gross proceeds of ~$30M. The offering consists of ~2.4M class A units priced at $3 apiece, with each unit consisting of one common stock, a Series A...
NEUROBO ANNOUNCES PRICING OF $30 MILLION UNDERWRITTEN PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT PR Newswire BOSTON , Nov. 4, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) (the "Company" or "NeuroBo") today announced the pric...
NeuroBo Pharmaceuticals ( NASDAQ: NRBO ) received Nasdaq notification indicating that the company has evidenced full compliance with the minimum bid price requirement As a result, the listing matter has been closed. Shares are trading up 4% premarket. For fur...
NeuroBo Pharmaceuticals, Inc. Compliant with All Applicable Nasdaq Listing Criteria PR Newswire BOSTON , Sept. 29, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. ("NeuroBo") (Nasdaq: NRBO) today announced that on September 27, 2022 , NeuroBo recei...
News, Short Squeeze, Breakout and More Instantly...
NeuroBo Pharmaceuticals Inc. Company Name:
NRBO Stock Symbol:
NASDAQ Market:
NeuroBo Pharmaceuticals Inc. Website:
NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01 PR Newswire CAMBRIDGE, Mass. , July 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transfo...
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Top-Line Data Readout From the Single Ascending Dose Part 1 Expected in the Third Quarter of 2024, and From the Multiple Asce...
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon ...